MX2016011045A - Terapia de combinacion para cancer. - Google Patents
Terapia de combinacion para cancer.Info
- Publication number
- MX2016011045A MX2016011045A MX2016011045A MX2016011045A MX2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A MX 2016011045 A MX2016011045 A MX 2016011045A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- combination therapy
- fluoro
- treating
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención se refiere a la preparación de medicamentos para uso en el tratamiento y métodos para tratar cáncer de pulmón de células no pequeñas en un paciente que comprende [5-(4-etil-piperazin-1-ilmetil)-piridin-2-il]-[5-fluoro-4-(7-fluo ro-3-isopropil-2-metil-3H-benzoimidazol-5-il)-pirimidin-2-il]-ami na, o una sal de la misma farmacéuticamente aceptable, en combinación, como se describe, además, con un anticuerpo anti-VEGFR2, preferiblemente, ramucirumab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461944811P | 2014-02-26 | 2014-02-26 | |
PCT/US2015/016529 WO2015130540A1 (en) | 2014-02-26 | 2015-02-19 | Combination therapy for cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016011045A true MX2016011045A (es) | 2016-10-28 |
Family
ID=52630493
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016011045A MX2016011045A (es) | 2014-02-26 | 2015-02-19 | Terapia de combinacion para cancer. |
Country Status (18)
Country | Link |
---|---|
US (1) | US10238656B2 (es) |
EP (1) | EP3110444B1 (es) |
JP (1) | JP5948525B1 (es) |
KR (1) | KR20160111001A (es) |
CN (1) | CN106029097A (es) |
AP (1) | AP2016009402A0 (es) |
AU (1) | AU2015223359B2 (es) |
BR (1) | BR112016016880A2 (es) |
CA (1) | CA2936558A1 (es) |
EA (1) | EA201691385A1 (es) |
ES (1) | ES2659424T3 (es) |
IL (1) | IL246761A0 (es) |
MA (1) | MA39294B1 (es) |
MX (1) | MX2016011045A (es) |
MY (1) | MY176219A (es) |
SG (1) | SG11201606958YA (es) |
TW (1) | TWI558399B (es) |
WO (1) | WO2015130540A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201625304A (zh) * | 2014-10-24 | 2016-07-16 | 美國禮來大藥廠 | 泌尿上皮癌之療法 |
EP3442572A1 (en) * | 2016-04-15 | 2019-02-20 | Eli Lilly and Company | Combination therapy of ramucirumab and abemaciclib for use in treatment of mantle cell lymphoma |
CN109689641B (zh) * | 2016-09-09 | 2020-11-03 | 正大天晴药业集团股份有限公司 | 一种取代的2-氢-吡唑衍生物的晶型、盐型及其制备方法 |
CN109952315A (zh) * | 2016-11-16 | 2019-06-28 | 伊莱利利公司 | 用于转移性结直肠癌的治疗 |
EP3752500A1 (en) | 2018-04-05 | 2020-12-23 | Johnson Matthey Public Limited Company | Solid-state forms of abemaciclib, their use and preparation |
EP3773914A1 (en) * | 2018-04-06 | 2021-02-17 | Eli Lilly and Company | Ramucirumab for the treatment of cancers in pediatric patients |
WO2020239051A1 (zh) * | 2019-05-30 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | Cdk4/6抑制剂与vegfr抑制剂联合在制备治疗肿瘤的药物中的用途 |
WO2021030843A1 (en) | 2019-08-13 | 2021-02-18 | Johnson Matthey Public Limited Company | Solid-state forms of abemaciclib, their use and preparation |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030108545A1 (en) * | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US7498414B2 (en) * | 2002-03-04 | 2009-03-03 | Imclone Systems Incorporated | Human antibodies specific to KDR and uses thereof |
CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
US20050106667A1 (en) | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
JO2885B1 (en) * | 2008-12-22 | 2015-03-15 | ايلي ليلي اند كومباني | Protein kinase inhibitors |
UY33226A (es) * | 2010-02-19 | 2011-09-30 | Novartis Ag | Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6 |
-
2015
- 2015-02-13 TW TW104105148A patent/TWI558399B/zh not_active IP Right Cessation
- 2015-02-19 ES ES15708638.0T patent/ES2659424T3/es active Active
- 2015-02-19 MY MYPI2016703120A patent/MY176219A/en unknown
- 2015-02-19 SG SG11201606958YA patent/SG11201606958YA/en unknown
- 2015-02-19 MX MX2016011045A patent/MX2016011045A/es unknown
- 2015-02-19 CN CN201580010432.3A patent/CN106029097A/zh active Pending
- 2015-02-19 WO PCT/US2015/016529 patent/WO2015130540A1/en active Application Filing
- 2015-02-19 US US15/115,995 patent/US10238656B2/en not_active Expired - Fee Related
- 2015-02-19 AU AU2015223359A patent/AU2015223359B2/en not_active Expired - Fee Related
- 2015-02-19 EP EP15708638.0A patent/EP3110444B1/en active Active
- 2015-02-19 EA EA201691385A patent/EA201691385A1/ru unknown
- 2015-02-19 MA MA39294A patent/MA39294B1/fr unknown
- 2015-02-19 JP JP2016505628A patent/JP5948525B1/ja not_active Expired - Fee Related
- 2015-02-19 AP AP2016009402A patent/AP2016009402A0/en unknown
- 2015-02-19 KR KR1020167022971A patent/KR20160111001A/ko active Search and Examination
- 2015-02-19 CA CA2936558A patent/CA2936558A1/en not_active Abandoned
- 2015-02-19 BR BR112016016880A patent/BR112016016880A2/pt not_active Application Discontinuation
-
2016
- 2016-07-13 IL IL246761A patent/IL246761A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
TWI558399B (zh) | 2016-11-21 |
WO2015130540A1 (en) | 2015-09-03 |
KR20160111001A (ko) | 2016-09-23 |
MY176219A (en) | 2020-07-24 |
IL246761A0 (en) | 2016-08-31 |
MA39294A1 (fr) | 2018-06-29 |
BR112016016880A2 (pt) | 2017-10-03 |
EA201691385A1 (ru) | 2016-12-30 |
AP2016009402A0 (en) | 2016-08-31 |
CN106029097A (zh) | 2016-10-12 |
SG11201606958YA (en) | 2016-09-29 |
AU2015223359B2 (en) | 2017-06-01 |
AU2015223359A1 (en) | 2016-08-11 |
US10238656B2 (en) | 2019-03-26 |
EP3110444B1 (en) | 2018-01-03 |
EP3110444A1 (en) | 2017-01-04 |
TW201542209A (zh) | 2015-11-16 |
JP2016521262A (ja) | 2016-07-21 |
ES2659424T3 (es) | 2018-03-15 |
MA39294B1 (fr) | 2018-12-31 |
US20170173013A1 (en) | 2017-06-22 |
JP5948525B1 (ja) | 2016-07-06 |
CA2936558A1 (en) | 2015-09-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016011045A (es) | Terapia de combinacion para cancer. | |
AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
MY202377A (en) | Treating gastric cancer using combination therapies comprising liposomal irinotecan, oxaliplatin, 5-fluorouracil (and leucovorin) | |
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
PH12015502780A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
MX2018014175A (es) | Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso. | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
PH12015500758A1 (en) | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | |
MX2021004821A (es) | Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia. | |
MX2018001802A (es) | Metodos para el tratamiento del cancer de pancreas metastasico con el uso de terapias de combinacion que comprenden irinotecan liposomal y oxaliplatino. | |
MY186977A (en) | Tetrasubstituted alkene compounds and their use | |
MY191040A (en) | Therapy involving antibodies against claudin 18.2 for treatment of cancer | |
SG10201902598VA (en) | Peptidomimetic macrocycles and formulations thereof | |
MX2016011295A (es) | Terapia para cancer con anticuerpos anti-met en combinacion con anti-vegfr2. | |
AU2015267099A8 (en) | Use of eribulin in the treatment of cancer | |
PH12018502422A1 (en) | Nanoliposomal irinotecan for use in treating small cell lung cancer | |
MX2018010223A (es) | Terapia combinada para tratamiento de cancer de ovario. | |
EP3639829A4 (en) | USE OF ISOVALERYLSPIRAMYCIN I, II AND / OR III IN THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT AND / OR PREVENTION OF A TUMOR, AND A MEDICINAL PRODUCT | |
MX2018008640A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano. | |
PH12015502564B1 (en) | Pyridone derivatives for the treatment of viral infections and further diseases | |
MX2015015601A (es) | Metodo para el tratamiento de cancer pulmonar por vacunacion con el lipopeptido mucina 1 (muc-1). | |
EP3735261A4 (en) | GROWTH FACTOR TGFSS1 OR TGFSS2 OR TGFSS3 FOR USE IN ANTI-CANCER THERAPY FOR PATIENTS WITH TUMORS IN WHICH AT LEAST PART OF THE CELLS EXPRESS EGFRVIII | |
UA98544U (uk) | Спосіб лікування ендогенної інтоксикації у хворих на хронічне обструктивне захворювання легень | |
NZ725567A (en) | R-spondin translocations and methods using the same | |
UA93647U (uk) | Спосіб лікування латентної ішемічної хвороби серця у хворих на бронхіальну астму |